Political and economic uncertainty hangs over the industry, while major bets on metabolic and immune disease drug research are set to play out.

The results suggest Bayer’s elinzanetant may help a broader group of women with vasomotor symptoms, which are associated with ...

German pharma major Bayer today announced top-line results of the Phase III study OASIS 4 investigating elinzanetant as ...

Vividion Therapeutics, a California-based biotech owned by Bayer, is acquiring Tavros Therapeutics, a precision oncology ...

Thursday, Bayer shared top-line data from a phase 3 trial that tested elinzanetant in women on adjuvant endocrine therapy for ...

Bayer said its Elinzanetant drug, which targets some symptoms produced by endocrine therapy in women with breast cancer, met all primary and secondary endpoints in a study. The German pharmaceutical ...

Bayer Aktiengesellschaft (ETR:BAYN – Get Free Report) shares were up 0.4% on Wednesday . The stock traded as high as €19.99 ($20.61) and last traded at €19.79 ($20.40). Approximately 3,072,022 shares ...

Durham-based Tavros Therapeutics, a precision oncology company spun out of Duke University, has been acquired by a subsidiary of global life sciences titan Bayer AG. Financial terms of the deal with ...

In a bold move to restore profitability, Bayer CEO Bill Anderson cut out most of the company’s management roles last year.

The addition of Tavros greatly expands Vividion's functional genomics expertise and capabilities, bringing proprietary methods for genomic screening that can identify new target opportunities, as well ...

GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...